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Solid tumours often have insufficient blood supply, resulting in
regions with reduced oxygen concentrations (Vaupel et al, 1991).
Diffusion limited hypoxia is a characteristic of solid tumours
which has been appreciated for many years (Thomlinson and Gray,
1955). However, it is now recognized that hypoxic cells can also
arise from perfusion driven changes in oxygen supply, resulting in
rapid and reversible changes in oxygenation (Brown, 1979;
Chaplin et al, 1987; Kimura et al, 1996). Hypoxic cells are
resistant to radiation (Thomlinson and Gray, 1955) and to some
chemotherapeutic agents (Teicher et al, 1981; Hoeckel et al, 1999)
and are generally perceived as a hindrance to cancer therapy.
However, hypoxia is also a tumour characteristic which is poten-
tially exploitable using bioreductive drugs (Workman and
Stratford, 1993) or gene therapy (Dachs et al, 1997).
Hypoxia is a strong stimulus for gene expression. Hypoxic gene
regulation consists of two main components, namely an oxygen
sensitive transcription factor (hypoxia inducible factor-1, HIF-1)
and its recognition sequence (hypoxia regulatory element, HRE)
(for a recent review see O’Rourke et al, 1997). HIF-1 activity is
regulated primarily by low oxygen conditions, but also via specific
oncoproteins and tumour suppressors, such as p53 and the von
Hippel Lindau protein (for a recent review see Dachs and Tozer,
2000). The HIF-1/HRE system was found to be common to all
mammalian cells tested to date (Maxwell et al, 1993) and, recently,
the HIF-1α subunit was shown to be overexpressed in the majority
of clinical tumour samples tested (Zhong et al, 1999). We have
previously proposed a gene therapy approach based on HRE-
regulated gene expression which exploits the presence of severe
hypoxia in tumours for the induction of therapeutic genes (Dachs
et al, 1997). Chimeric promoters containing hypoxia regulated
enhancer sequences were shown to regulate the expression of the
marker gene CD2 both in tissue culture and in solid tumours in
response to hypoxia. In vitro work using the bacterial cytosine
deaminase in a gene directed enzyme prodrug therapy approach
demonstrated that the hypoxic induction of this gene could render
cells sensitive to the prodrug 5-fluorocytosine (Dachs et al, 1997).
The one fundamental question remaining from this work was
the feasibility of gene delivery to hypoxic regions of solid
tumours. Hypoxia reduces cell proliferation, induces growth arrest
and specifically inhibits replicon initiation in early S-phase within
8–24 h in most cells (for reviews see Giaccia, 1996; Wang and
Semenza, 1996). Even though some stress response genes (such as
the HIF-1 regulated genes) are up-regulated under hypoxia, the
majority of cell metabolism is decreased, with a reduction in
overall transcription and translation. Protein synthesis rates under
hypoxia (<0.01% O2) were reduced to 60% of the aerobic rate
(Heacock and Sutherland, 1986). A reduction in RNA and DNA
content of hypoxic cultures, as well as a reduction in the de novo
synthesis of nucleotides had also been reported (Loeffler, 1992).
These effects may prevent gene delivery to hypoxic cells in solid
tumours and therefore the effect of hypoxia on transfection effi-
ciency warranted further investigation.
The aim of this study was to analyse in vitro the feasibility of
gene uptake under conditions which mimic tumour hypoxia. A non-
viral transfection method was chosen for the study of hypoxic cell
transfection. This DNA delivery system, which consists of an inte-
grin-targeting peptide, lipofectin and plasmid DNA which combine
electrostatically to form a complex, has demonstrated efficient
transfection of a range of cell types (Hart et al, 1995, 1998).
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fluorescent activated cell sortingTransfection efficiencies of two commonly used marker genes and
viral promoters were recorded in a range of cell lines under different
oxygenation conditions. A simple in vitro model of hypoxia/reoxy-
genation was used to mimic the variable nature of tumour hypoxia.
MATERIALS AND METHODS
Cell lines and growth media
The human bladder carcinoma cell line T24 (European Collection
of Cell Cultures; Bubenik et al, 1973; Dirks et al, 1999), the immor-
talized human microvascular endothelial cell line HMEC-1 (Ades
et al, 1992), human squamous carcinoma cell line of the head and
neck FaDu (Rangan, 1972; American Type Culture Collection), the
mouse hepatoma cell line Hepa-1 wild type (clone Hepa-1c1c7)
and its derivative Hepa c4 (HIF-1β mutant; Hankinson, 1979) were
utilised. Only cells tested negative for mycoplasma were used in the
experiments, since it had been shown that mycoplasma interfered
with transfection, especially under hypoxia (results not shown). All
cells were maintained in Dulbecco’s MEM (DMEM, Life
Technologies, UK) with 10% fetal calf serum and L-glutamine in a
5% CO2 humidified incubator at 37° C.
Cell proliferation was monitored by cell counting using a
haemocytometer and trypan blue (0.2% final concentration,
Sigma) to distinguish live and dead cells.
Hypoxic conditions
Cells were plated 16–24 h prior to the experiment in oxygen
impermeable dishes (Permanox, Nunc, UK) at 1–5× 105/dish
(4–18× 103/cm2), depending on the growth rate of the cell line.
Hypoxic conditions were achieved by placing the dishes (with a
thin layer of pre-conditioned anoxic media above the cells) either
into sealed containers flushed continuously with humidified 1% or
0.1% O2 (in 5% CO2, balance N2) (BOC Gases, UK), or by placing
the dishes in an anaerobic glove cabinet (in an atmosphere of 5%
CO2, 5% H2, 90% N2, with palladium catalyst; Don Whitley
Scientific Ltd, UK). All hypoxic manipulations were carried out in
the anaerobic glove cabinet to minimise the amount of oxygen in
the hypoxic experiments by moving the sealed containers into the
glove cabinet. The media pH was monitored and found to be the
same in air and anoxic conditions (pH 7.5).
Transfection method
Cells were transfected using integrin-targeting peptides (sequence:
K16GACRRETAWACG) and lipids as described previously (Hart
et al, 1998). Briefly, a mixture was prepared containing lipofectin
(Life Technologies, UK), peptide and plasmid DNA at a ratio of
0.75:4:1 by weight in OptiMEM (Life Technologies). The mixture
was left at room temperature for 2 h for complex formation, then
diluted into OptiMEM. Cells were left to equilibrate for 2 h under
hypoxia or anoxia prior to transfection. After washing the cells in
phosphate buffered saline (PBS), the mixture was added to the
cells to transfect for 5 h (unless specified) at 37° C in air or
hypoxia. The number of cells expressing the marker proteins was
assessed 24 h later.
DNA plasmids and product detection
General molecular biology techniques were used for DNA manip-
ulations (Sambrook et al, 1989). The two marker genes, GFP
(green fluorescent protein) and CD4, and the two strong viral
promoters from cytomegalovirus (CMV) and simian virus (SV40),
were chosen for this work since they are commonly used in gene
regulation and transfection studies.
The commercially available plasmid pEGFP-N1 (Clontech,
UK) was employed; it contains the gene encoding the red-shifted,
enhanced variant of GFP under the control of the CMV promoter.
Direct detection of GFP (excitation 488 nm, emission 507 nm)
was done using fluorescent activated cell sorting (FACS, Becton
Dickinson, UK) and normalised to untransfected control cells
(Figure 1).
The pMACS4.1 (Milteyne Biotec) plasmid encodes a truncated
cell surface human CD4 protein under the control of the SV40
promoter. The plasmid pCMV-CD4 was produced as follows: the
CD4 encoding gene fragment (digestion of pMACS4.1 with Pst 1,
followed by Mung Bean nuclease digestion to blunt, followed by
EcoR 1 digestion) was ligated to the GFP-deleted backbone of
pEGFP-N1 (digestion of pEGFP-N1 with Not 1, followed by
Mung Bean nuclease digestion, followed by EcoR 1 digestion).
Enzymes and buffers were from Life Technologies. The
pMACS4.1 and pCMV-CD4 transfected cells were detected with
FITC-labelled anti-human CD4 Ab (Coulter, UK) using FACS and
normalised to untransfected, Ab-stained control cells.
Statistical analysis
Significance tests were carried out on the data groups using
analysis of variance (ANOVA) followed by the students t-test for
individual pairwise comparisons, with values of P < 0.05 consid-
ered as significant.
RESULTS
Transfection efficiency in air
The initial experiments were done to determine the optimal length
of transfection time. Bladder carcinoma T24 cells were exposed to
the delivery complex with pEGFP-N1 from 10 s to 7 h in air and
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Figure 1 FACS analysis of transiently transfected human cells.
Fluorescence of untransfected control cells (solid histogram), cells
transfected in air (–) or under anoxia (–) is measured using FACS analysis. A
typical scan for HMEC-1 cells following transfection with pEGFP-N1 is
shown. Transfection efficiency is defined as the % of cells (of a total of 104
cells analysed) with increased fluorescence above controls (within marker
M); < 1% of untransfected cells are contained in Manalysed for GFP fluorescence 24 h later (Figure 2). Half-maximal
transfection was achieved within 1 h. A plateau in transfection
efficiency was reached by 5 h transfection time and this transfec-
tion period was used in all subsequent experiments.
Transfection efficiency of a panel of mammalian cell lines,
including cancer cell lines and endothelial cells, using the peptide-
mediated gene delivery was analysed. Between 41 and 69% of
cells expressed the stabilized form of GFP 24 h after transfection
for 5 h with pEGFP-N1 in air (Figure 3, solid black bars). T24
bladder carcinoma cells showed the highest level of transfection,
while FaDu squamous carcinoma cells showed the lowest.
Analysis of growth characteristics showed that T24 cells grew
faster than FaDu cells (doubling times of about 18 h and 34 h,
respectively).
Hypoxic transfection efficiency: effect of O2
concentration and cell characteristics
The tranfection efficiency of mammalian cells was tested under a
range of oxygen concentrations (anoxia, 0.1%, 1% and 21% O2
during transfection with pEGFP-N1 complex and for 24 h after-
wards). The exposure to moderate hypoxia (0.1% and 1% O2) did
not significantly reduce transfection efficiency in any of the cell
lines tested, whereas severe hypoxia (anoxia) reduced it by 28 to
80%, depending on the cell line (Figure 3). In addition, in all cell
lines tested it was observed that anoxia reduced the number of
highly fluorescent cells (103-fold above autofluorescence) (Figure
1). These studies show that hypoxia can effect the transfection
and/or production of functional proteins in vitro depending on the
severity of oxygen deprivation and the cell line.
Anoxia had the least effect on transfection efficiency in the T24
cells and the most effect on FaDu cells. Growth characteristics
were unlikely to be the main determining factor here. Both showed
a total cessation of growth under anoxia, with anoxia-related cell
deaths of 7–13% after 31 h under anoxia (results not shown).
The lack of the hypoxic sensing mechanism appears to be a
significant factor of transfection efficiency under anoxia.
Comparing the mouse hepatoma cells Hepa wt with Hepa c4,
which are mutated for the HIF-1 transcription factor, transfection
tended to be slightly less efficient for the mutant cell line (Figure
3). A statistical analysis (two population students t-test) showed
this to be significant under anoxic conditions (P < 0.05).
Hypoxic transfection efficiency: effect of transient
anoxia
A system of changing oxygenation aimed at mimicking those tran-
sient hypoxic conditions found in solid tumours (Brizel et al, 1995;
Chaplin and Hill, 1995) was utilized to further test the effect of
tumour conditions on gene transfer. Reoxygenation of T24 cells
for different lengths of time (0–24 h) after anoxic transfection (2 h
+ 5 h anoxia) showed the same transfection efficiency as aerobic
controls (Figure 4A). The effect of anoxic pre-conditioning,
anoxic transfection or anoxic incubation after transfection on gene
transfer was analysed (Figure 4B). T24 cells were incubated in air
(o) or anoxia (a) prior to transfection (for 24 h), during transfec-
tion (for 5 h) and after transfection (for 24 h). Gene transfer under
long-term, chronic anoxia (aaa) differed significantly (P < 0.01)
from transfer under aerobic and transient anoxia (ooo, oao and
oaa) (Figure 4B). Transfection efficiency was similar in all other
treatment combinations.
Hypoxic transfection efficiency: effect of gene product
and promoter
The GFP chromophore is formed by a cyclization reaction and an
oxidation step that requires molecular oxygen (Cubitt et al, 1995).
It is also known that some gene promoters are regulated by
oxygenation. The effect of the gene product and the promoter on
hypoxic transfection efficiency in T24 cells was therefore tested.
Two plasmids were utilized; both encoding a truncated version of
the surface protein CD4, either under the control of the SV40
(pMACS4.1) or the CMV promoter (pCMV-CD4), and compared
them to the pEGFP-N1 plasmid (CMV-controlled GFP). A higher
percentage of cells expressed GFP following transfection than
CD4 under any given oxygenation condition (P < 0.05, with the
exception of pMACS4.1 under 1% O2, Figure 5). Oxygenation had
no effect on transfection efficiency in cells transfected with either
664 GU Dachs et al
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Figure 2 Lengh of transfection time affects percentage of transfected cells.
The % of transfected T24 cells increased over time of treatment with a
peptide-targeted lipofectin vector containing pEGFP-N1; half maximum
transfection was achieved within 1 h and maximal transfection was achieved
within 5 h. Means of at least 3 independent experiments, in duplicate, 
± standard error (SE) are shown
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Figure 3 Transfection efficiency in mammalian cell lines with pEGFP-N1
under different oxygenation conditions. Anoxia reduced transfection
significantly (* P < 0.01 by students t-test) in all five cell lines compared to
both air and moderate hypoxia (except for T24 at 1% O2). Hepac 4 cells
showed a significantly reduced transfection efficiency compared to Hepa wt
under anoxia (* P<0.05). Means of at least 3 independent experiments, in
duplicate, ± SE are shownCMV promoter-controlled GFP or CD4 DNA constructs.
However, T24 cells transfected with the DNA construct encoding
CD4 under SV40 promoter-control showed a significant reduction
in transfection efficiency under anoxia compared to the aerobic
control (by 64%) and mild hypoxia (Figure 5). The reduced 
anoxic transfection efficiency observed in cells transfected with
pMACS4.1 appears therefore to depend mostly on the SV40
promoter rather than the gene product in this cell line.
DISCUSSION
Gene delivery remains the main stumbling block in the gene
therapy of cancer. Both viral and non-viral delivery methods are
under intense investigation, with non-viral means holding the
promise of safety and specificity. The introduction of foreign gene
products into human cells consists of a sequence of discrete steps.
First the vector must bind to the cell surface, then enter the cell by
an endocytic or phagocytic process. Efficient escape from the
vesicle is necessary to evade enzymatic degradation in the acidi-
fied environment of the maturing endosome. Finally the DNA
must enter the nucleus either by penetrating the envelope through
the nuclear pores or during mitosis when the envelope breaks
down. The persistence of gene expression can be limited by shut-
off of promoters, restrictive methylation or one or more of a
number of post-transcriptional events. For most cancer gene
therapy strategies, however, such as suicide gene therapy or
immunotherapy, transient gene expression should be sufficient.
The DNA delivery system used in this investigation consists 
of integrin-targeting peptides, lipofectin and plasmid DNA (Hart
et al, 1995, 1998). The peptide portion of the delivery system
contains a 16-lysine DNA-binding domain and one of a number of
integrin-binding domains. The cationic charge properties of the
complex, derived from the peptide, contribute to non-specific cell
binding and transfection properties (Hart et al, 1998). The lipid
component acts as an adjuvant to transfection by mediating endo-
somal escape of the plasmid component.
Integrins are membrane glycoproteins important for attachment
of cells to the extracellular matrix, cell–cell interactions, migration
and signalling events (for a review see Hynes, 1992). They are also
exploited for cell binding and entry by a number of bacterial and
viral pathogens. Therefore, the advantage of this approach is that it
mimics cell entry of pathogens via integrin receptors. Integrins on
cancer cells play important roles in tumour growth, angiogenesis
and metastasis. Integrin expression patterns in tumour cells often
differ from their normal counterparts, offering windows of oppor-
tunity for tumour-specific transfection.
Using this gene transfer system a plateau of maximal transfec-
tion efficiency of about 70% was reached within 5 h. In T24 cells a
residual 20–30% of cells remained refractive to transfection, even
after 24 h of transfection (results not shown), which may be a cell
cycle effect. The effect of cell proliferation on transfection effi-
ciency remains unclear. While some of our preliminary observa-
tions showed no effect of cell cycle on transfection (by DNA
staining and FACS analysis), others showed that non-cycling
aerobic cells (using more confluent cultures) were more difficult to
transfect (unpublished data) and cells with increased proliferation
transfected more efficiently (comparing T24 and FaDu cells in
Figure 3).
The tumour microenvironment is characterized by high intersti-
tial fluid pressure, low extracellular pH, temporally and spatially
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Figure 4 Transfection efficiency of T24 cells under changing oxygenation
conditions. (A) Effect of reoxygenation on transfection efficiency. Transfection
conditions: anoxic transfection and 0–24 h post-transfection anoxia. (B)
Effect of pre- or post-anoxia treatment on transfection efficiency. Transfection
conditions: 24 h pre-transfection, 5 h transfection, 24 h post-transfection; 
O = incubation in air, a = incubation under anoxia. Transfection under chronic
anoxia (aaa) differs significantly from normoxia and intermittent anoxia (ooo,
oao, oaa); * P < 0.01 by students t-test. Means of at least 3 independent
experiments, in duplicate, ± SE are shown
Figure 5 Effect of gene product or promoter on transfection in T24 cells
under a range of oxygenation conditions. DNA constructs used: pEGFP-N1
(CMV promoter – GFP), pCMV-CD4 (CMV promoter – truncated CD4),
pMACS4.1 (SV40 promoter – truncated CD4). Only transfection efficiencies
with pMACS4.1 under anoxia are significantly reduced compared to
transfection with any other construct under any conditions; * P < 0.01 by
students t-test. Means of at least 3 independent experiments, in duplicate, ±
SE are shown666 GU Dachs et al
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heterogeneous blood flow and hypoxia (Helmlinger et al, 1997)
which are all a challenge for gene delivery. In this paper we
focused on hypoxia as a potential problem in gene tranfection as it
is the chemo- and radio-resistant hypoxic cells that we wish to
target for our gene therapy strategy. In addition, although a set of
stress response genes are specifically induced by hypoxia, tumour
hypoxia is known to reduce overall transcription and protein
production which could reduce transfection efficiency (Heacock
and Sutherland, 1986; for a recent review see Dachs and Chaplin,
1998). The effect of hypoxia on gene delivery therefore required
careful analysis prior to the further development of hypoxia-
targeted gene therapy.
Hypoxic transfection efficiencies varied between the cell lines
tested. Although transfection, using this non-viral gene delivery
system, has previously been shown to be largely integrin mediated
(Hart et al, 1998), no integrin specificity could be demonstrated in
this study and transfer was believed to be mostly charge mediated
(own observations). Integrin expression, which is modulated by
hypoxia (anoxia decreased and 1% O2 increased integrins α Vβ 3
and α 5β 1 slightly in T24 and HMEC-1 cells; results not shown), is
therefore not a factor in determining the effectiveness of transfec-
tion under hypoxia in this system. On the other hand, the HIF-1
hypoxia response system appeared to be one significant, although
minor, factor in determining anoxic transfection efficiencies
(comparing Hepa wt and Hepa c4 in Figure 3).
Anoxia (0 mmHg) has been measured in solid tumours
(Hoeckel et al, 1991; Vaupel et al, 1991), but it is currently unclear
whether that subpopulation of cells contributes to the outcome of
cancer treatment, as they may be completely necrotic. Cells at
oxygenation conditions below 2.5 mmHg (roughly 0.3% O2) are
known to be significantly more resistant to the effects of ionising
radiation than aerated cells. The anoxic conditions achieved using
an anaerobic glove compartment with palladium catalyst are more
stringent than gassing with a mixture of 95% N2, 5% CO2 (own
observations, also Dachs et al, 1997). The chronic anoxia used in
this paper was chosen as an extreme case and showed that even
under these severe conditions some level of transfection was
possible. The findings that radio-biologically relevant hypoxia
(0.1% O2) did not reduce gene transfer is encouraging for future
gene therapy strategies. Furthermore, conditioning cells with
anoxia prior to or after transfections had little effect on transfec-
tion efficiency, which indicates that transient hypoxia in tumours is
unlikely to reduce gene transfer.
An additional challenge to gene transfer, which is the ability of
the delivery vehicle to penetrate through multicell layers, requires
future analysis. This challenge may be a problem if the main target
for gene therapy is the population of chronic hypoxic tumour cells
at a distance from the nearest blood vessel. However, a more likely
target may be the transient hypoxic population of cells in the
tumour, especially endothelial cells lining the blood vessels.
Tumour microvessels have been shown to be subject to acute
periods of hypoxia in vivo (Kimura et al, 1996). Targeting
endothelial cells for hypoxia-selective gene therapy has several
advantages: endothelial cells are systemically accessible, are not
transformed and support large numbers of tumour cells. Data
presented in this paper show that hypoxic human endothelial cells
can be transfected.
When analysing transfection efficiencies the choice of marker
gene is important. In this paper all cells transiently transfected 
with GFP under anoxic conditions showed a reduction in highly
fluorescent cells (thousand-fold above autofluorescence) when
compared to those transfected in air or mild hypoxia. It is known
that the marker protein GFP requires molecular oxygen to fold
correctly and fluoresce (Cubitt et al, 1995). Analysis of stable GFP
transfectants had shown that anoxia reduced GFP fluorescence,
whereas less severe hypoxia (including gassing with 95% N2, 5%
CO2) did not significantly alter GFP fluorescence (Coralli et al,
manuscript in preparation). In an attempt to avoid hypoxic effects
on the detection of the marker gene GFP, a second marker gene,
encoding the truncated CD4, was used. Oxygenation conditions
made no significant difference to transfection of either gene
product under CMV promoter control (Figure 5). However, a
difference in transfection efficiency under anoxia was observed
when the marker genes were controlled by different promoters. A
significant reduction in anoxic transfection efficiency was
observed in T24 cells transfected with the SV40-controlled marker
gene and not with CMV-controlled marker genes. Both the CMV
and SV40 promoters originate from viruses and are used widely as
strong constitutive regulators of gene expression. From the results
presented here it appears that expression controlled by the SV40
promoter is more oxygen sensitive then that controlled by the
CMV promoter.
In conclusion, transfection efficiencies were shown to be signif-
icantly effected by cell line characteristics, the gene promoter and
severe tumour conditions such as anoxia. The fact that neither
intermediate hypoxia nor intermittent anoxia had significant detri-
mental effects on gene transfer is promising for future hypoxia-
targeted gene therapy strategies.
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